Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 7 Results

Title
Intervention Indication Therapeutic Area Year Actions
Upadacitinib for active psoriatic arthritis with inadequate response to biological or non-biological DMARDs Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Psoriatic arthritis Dermatology , Rheumatology 2019 View  |  Download
Upadacitinib for Adults with Moderate to Severe Active Rheumatoid Arthritis After Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) or Biologic DMARDs Failure Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Rheumatoid arthritis Rheumatology 2017 View  |  Download
Upadacitinib for Ankylosing Spondylitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Ankylosing spondylitis Musculoskeletal System 2020 View  |  Download
Upadacitinib for atopic dermatitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Atopic dermatitis Dermatology 2019 View  |  Download
Upadacitinib for moderate to severe active Crohn’s disease Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
Upadacitinib for non-radiographic axial spondyloarthritis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Axial spondyloarthritis Rheumatology 2021 View  |  Download
Upadacitinib for ulcerative colitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Ulcerative colitis Gastroenterology 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications